Mineralys Therapeutics (MLYS) Projected to Post Quarterly Earnings on Wednesday

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) will likely be releasing its earnings data before the market opens on Wednesday, February 12th. Analysts expect Mineralys Therapeutics to post earnings of ($1.00) per share for the quarter. Individual that are interested in participating in the company's earnings conference call can do so using this link.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its earnings results on Monday, November 11th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same quarter in the prior year, the business posted ($0.57) earnings per share. On average, analysts expect Mineralys Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Mineralys Therapeutics Price Performance

Shares of MLYS traded up $0.15 during trading hours on Tuesday, hitting $9.66. The stock had a trading volume of 307,912 shares, compared to its average volume of 264,460. The firm has a market capitalization of $480.78 million, a P/E ratio of -2.95 and a beta of 1.44. Mineralys Therapeutics has a 1-year low of $8.58 and a 1-year high of $16.91. The firm has a 50 day simple moving average of $11.31 and a 200-day simple moving average of $12.06.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a report on Tuesday, November 12th.

Insider Buying and Selling

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $9.10, for a total value of $97,888.70. Following the transaction, the chief financial officer now directly owns 226,097 shares in the company, valued at approximately $2,057,482.70. This trade represents a 4.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jon Congleton sold 18,333 shares of the firm's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $9.06, for a total transaction of $166,096.98. Following the sale, the chief executive officer now owns 877,608 shares in the company, valued at $7,951,128.48. The trade was a 2.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 33.24% of the stock is owned by company insiders.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.